目的 探討安絡(luò)化纖丸聯(lián)合復(fù)方牛胎肝提取物片治療乙型肝炎肝硬化臨床療效。方法 選取2013年5月-2015年5月在上海市普陀區(qū)中心醫(yī)院接受治療的乙型肝炎肝硬化患者84例,根據(jù)治療方案的差別分為對照組和治療組,每組各42例。對照組口服復(fù)方牛胎肝提取物片,2片/次,3次/d。治療組在對照組基礎(chǔ)上口服安絡(luò)化纖丸,1袋/次,2次/d。兩組患者均治療6個月。觀察兩組的臨床療效,比較兩組治療前后肝功能、肝纖維化指標(biāo)及門靜脈系統(tǒng)指標(biāo)變化情況。結(jié)果 治療后,對照組和治療組的總有效率分別為76.19%、92.86%,兩組總有效率比較差異有統(tǒng)計學(xué)意義(P<0.05)。治療后,兩組患者丙氨酸轉(zhuǎn)氨酶(ALT)、天冬氨酸轉(zhuǎn)氨酶(AST)和總膽紅素(TBIL)水平均顯著下降,白蛋白(ALB)水平顯著升高,同組治療前后差異有統(tǒng)計學(xué)意義(P<0.05);且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對照組,兩組比較差異具有統(tǒng)計學(xué)意義(P<0.05)。治療后,兩組患者透明質(zhì)酸(HA)、黏連蛋白(LN)、Ⅲ型前膠原(PC-III)和Ⅳ型膠原(C-IV)水平均顯著下降,同組治療前后差異有統(tǒng)計學(xué)意義(P<0.05);且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對照組,兩組比較差異具有統(tǒng)計學(xué)意義(P<0.05)。治療后,兩組患者門靜脈內(nèi)徑、脾臟厚度及脾靜脈寬度均下降,同組治療前后差異有統(tǒng)計學(xué)意義(P<0.05);且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對照組,兩組比較差異具有統(tǒng)計學(xué)意義(P<0.05)。結(jié)論 安絡(luò)化纖丸聯(lián)合復(fù)方牛胎肝提取物片治療乙型肝炎肝硬化的臨床療效顯著,能有效改善患者肝功能和肝纖維化,具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Anluo Huaxian Pills combined with Compound Embryonic Bovine Liver Extract Tablets in treatment of HBV-related hepatic cirrhosis. Methods Patients (84 cases) with HBV-related hepatic cirrhosis in Shanghai Putuo District Central Hospital from May 2013 to May 2015 were enrolled in this study. According to the different treatment plans, patients were divided into control group and treatment group, and each group had 42 cases. The patients in the control group were po administered with Compound Embryonic Bovine Liver Extract Tablets, 2 tablets/time, three times daily. The patients in the treatment group were po administered with Anluo Huaxian Pills on the basis of control group, 6 bag/time, twice daily. The patients in two groups were treated for 6 months. After treatment, the clinical efficacy was evaluated, and the changes of liver function, liver fibrosis indexes, and portal vein system indexes in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 76.19% and 92.86%, respectively, and there was difference between two groups (P< 0.05). After treatment, the levels of ALT, AST, and TBIL in two groups were significantly decreased, but the level of ALB in two groups was significantly increased, and the differences were statistically significant in the same group (P< 0.05). These observational indexes in the treatment group were better than those in the control group, with significant differences between two groups (P< 0.05). After treatment, the level of HA, LN, PC-III, and C-IV in two groups were significantly decreased, and the differences were statistically significant in the same group (P< 0.05). These observational indexes in the treatment group were better than those in the control group, with significant differences between two groups (P< 0.05). After treatment, the portal vein diameter, spleen thickness, and splenic vein width in two groups were significantly decreased, and the differences were statistically significant in the same group (P< 0.05). These observational indexes in the treatment group were better than those in the control group, with significant differences between two groups (P< 0.05). Conclusion Anluo Huaxian Pills combined with Compound Embryonic Bovine Liver Extract Tablets has clinical curative effect in treatment of HBV-related hepatic cirrhosis, and can improve liver function and liver fibrosis, which has a certain clinical application value.